Skip to main content
Medical information Clinical review pending

Genetic Testing

Msh2 Gene Muir-Torre Syndrome Genetic Test

This genetic test identifies mutations in the MSH2 gene associated with Muir-Torre syndrome, which increases the risk of certain cancers like colorectal and skin cancers. Understanding your genetic risk is key for early detection and management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), Extracted DNA, or One drop of blood on an FTA card.
Results
3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
A clinical history of the patient is required. A genetic counseling session to draw a pedigree chart of affected family members is recommended prior to testing. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Msh2 Gene Muir-Torre Syndrome Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Family history of Muir-Torre syndrome
  • ✓Personal history of multiple skin tumors (sebaceous adenomas, sebaceous carcinomas)
  • ✓Early-onset colorectal cancer
  • ✓Family history of related cancers
  • ✓To assess genetic predisposition to Muir-Torre syndrome
  • ✓To guide cancer surveillance and prevention strategies
02

In plain language

What this test helps you understand

Identifies mutations in the MSH2 gene associated with Muir-Torre syndrome, which increases the risk of certain cancers. Helps assess individual cancer risk and guide preventive strategies.
The MSH2 Gene Muir-Torre Syndrome NGS Genetic DNA Test is designed to identify mutations in the MSH2 gene. These mutations are linked to an increased risk of developing specific cancers, including colorectal cancer and skin cancers, characteristic of Muir-Torre syndrome. Knowing your genetic predisposition is important for proactive health management.

This test uses Next Generation Sequencing (NGS) technology to detect alterations in the MSH2 gene. Identifying these mutations helps healthcare providers assess an individual's cancer risk and recommend appropriate surveillance or preventive strategies.

Individuals with a family history of Muir-Torre syndrome or related cancers may benefit from this test. Symptoms to be aware of include multiple skin tumors (like sebaceous adenomas or carcinomas) and colorectal cancer, especially if diagnosed at a young age. Other associated cancers can also occur.

Taking this test offers several benefits, including early identification of genetic cancer risks, enabling informed decisions about screening and prevention. It can also provide valuable information for other family members regarding their potential risks. Discussing results with a healthcare provider or genetic counselor is crucial for understanding the implications and planning appropriate follow-up care.

This test is available at our facilities across Kenya, and we offer convenient home sample collection services. Contact us to learn more or schedule your test.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history of the patient is required. A genetic counseling session to draw a pedigree chart of affected family members is recommended prior to testing. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube), Extracted DNA, or One drop of blood on an FTA card.
MethodologyNext Generation Sequencing (NGS)
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the MSH2 gene. It does not detect mutations in other genes associated with Muir-Torre syndrome or other cancer predisposition syndromes. A negative result does not completely rule out genetic risk. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Muir-Torre syndrome is a rare genetic condition that increases the risk of developing certain types of cancer, particularly colorectal cancer and skin tumors like sebaceous adenomas and sebaceous carcinomas.
Individuals with a personal or family history of Muir-Torre syndrome, multiple skin tumors, or early-onset colorectal cancer should consider this test.
A positive result indicates that a mutation associated with an increased risk of Muir-Torre syndrome was found in the MSH2 gene. It is important to discuss this result with a healthcare provider to understand the implications for your health.
A negative result means no mutations associated with Muir-Torre syndrome were detected in the MSH2 gene. However, it does not completely eliminate the risk of developing cancer.
A sample can be collected as a blood draw, using extracted DNA, or via a single drop of blood on an FTA card. Home sample collection is available.
The typical turnaround time is 3 to 4 weeks. Confirm with the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp